Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Shorted: Short Interest Up 8,308.0% in October

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 818,602 shares, an increase of 8,308.0% from the September 30th total of 9,736 shares. Approximately 29.5% of the shares of the company are sold short. Based on an average daily volume of 30,928,638 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Alaunos Therapeutics Stock Down 9.6%

NASDAQ:TCRT traded down $0.20 during mid-day trading on Tuesday, hitting $1.93. 139,432 shares of the company traded hands, compared to its average volume of 2,340,624. The stock’s fifty day moving average price is $1.62 and its 200-day moving average price is $2.36. Alaunos Therapeutics has a one year low of $0.72 and a one year high of $4.50. The firm has a market cap of $6.37 million, a price-to-earnings ratio of -1.01 and a beta of -0.87.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc is a biotechnology company focused on developing genetically engineered T-cell therapies for the treatment of cancer, particularly solid tumors. Its research centers on T-cell receptor (TCR) therapies, which are designed to equip a patient’s immune cells to recognize and attack tumor-specific targets.

The company’s development programs have included TCR-T candidates directed at cancer-associated antigens such as NY-ESO-1 and LAGE-1a. Alaunos has also worked on a TCR library approach intended to support the development of personalized therapies targeting tumor mutations.